Foci Pharmaceutical(SZ:002644)2022-12-06 09:34Group 1: Financial Performance - The company's revenue growth in the third quarter was modest, while net profit saw a significant increase due to effective product structure adjustments and improved gross margins [1][2] - The company has enhanced its financial management efficiency, utilizing idle funds for investment, which contributed to net profit growth [2] Group 2: Market Development - The company has focused on expanding its hospital market, establishing a dedicated division that has significantly increased its market share, with over 70 products entering the hospital market, including 8 exclusive varieties [2] - The company is actively responding to national policies on tiered diagnosis and essential drug supply, preparing resources for further market expansion [2] Group 3: Export Business - The company exports to over 20 countries, with significant markets in the USA, Japan, Indonesia, and Australia, achieving stable growth in export business despite global economic challenges [3] - The company is seeking breakthroughs in product exports and international brand promotion, supported by national policies and initiatives like the Belt and Road [3] Group 4: Raw Material Costs and Future Plans - The company has made sufficient preparations for potential price increases in raw materials due to drought conditions, minimizing short-term cost impacts [4] - There are currently no plans for mergers or acquisitions, as the company awaits specific policies from local governments regarding state-owned enterprise reforms [4]